[1] SUN Y Q, MENG F Y, HAN M Z, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study[J]. Biol Blood Marrow Transplant, 2015, 21(6):1117-1126.
[2] TISSOT F, AGRAWAL S, PAGANO L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J]. Haematologica, 2017, 102(3):433-444. doi:  10.3324/haematol.2016.152900
[3] PAGANO L, CAIRA M, NOSARI A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project[J]. Haematologica, 2011, 96(9):1366-1370. doi:  10.3324/haematol.2011.042598
[4] 中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10):754-763. doi:  10.3760/cma.j.cn112138-20200627-00624
[5]

GODOY M C B, FERREIRA DALLA PRIA H R, TRUONG M T, et al. Invasive fungal pneumonia in immunocompromised patients[J]. Radiol Clin North Am, 2022, 60(3):497-506. doi:  10.1016/j.rcl.2022.01.006
[6]

BUSCA A, CINATTI N, GILL J, et al. Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the Turin experience[J]. Front Cell Infect Microbiol, 2021, 11:805514.
[7]

ALMYROUDIS N G, SUTTON D A, FOTHERGILL A W, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents[J]. Antimicrob Agents Chemother, 2007, 51(7):2587-2590. doi:  10.1128/AAC.00452-07
[8]

CUENCA-ESTRELLA M, GOMEZ-LOPEZ A, MELLADO E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi[J]. Antimicrob Agents Chemother, 2006, 50(3):917-921.
[9]

MAERTENS J A, RAHAV G, LEE D G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial[J]. Lancet, 2021, 397(10273):499-509. doi:  10.1016/S0140-6736(21)00219-1
[10] 上海市医疗保障局, 上海市人力资源和社会保障局, 上海市卫生健康委员会, 等. 关于印发《上海市基本医疗保险、工伤保险和生育保险药品目录(2022年)》的通知[EB/OL].(2023-10-10)[2023-2-24]. http://ybj.sh.gov.cn/qtwj/20230227/fb9048f18db94531bc59fe11e9e0b071.html.
[11]

FLOROS L, KUESSNER D, POSTHUMUS J, et al. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden[J]. BMC Infect Dis, 2019, 19(1):134. doi:  10.1186/s12879-019-3683-2
[12]

FLOROS L, PAGLIUCA A, TAIE A A, et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom[J]. J Med Econ, 2020, 23(1):86-97.
[13]

AZANZA J R, GRAU S, VÁZQUEZ L, et al. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain[J]. Mycoses, 2021, 64(1):66-77. doi:  10.1111/myc.13189
[14]

HUANG W K, ZHENG Y, HUANG H P, et al. External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy[J]. Eur J Clin Pharmacol, 2022, 78(9):1447-1457. doi:  10.1007/s00228-022-03359-2
[15]

HUANG H P, LIU Q X, ZHANG X H, et al. External evaluation of population pharmacokinetic models of busulfan in Chinese adult hematopoietic stem cell transplantation recipients[J]. Front Pharmacol, 2022, 13:835037. doi:  10.3389/fphar.2022.835037
[16]

RAAD I I, HANNA H A, BOKTOUR M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin[J]. Leukemia, 2008, 22(3):496-503.
[17]

CHAMILOS G, LEWIS R E, KONTOYIANNIS D P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis[J]. Clin Infect Dis, 2008, 47(4):503-509. doi:  10.1086/590004
[18]

MARTY F M, OSTROSKY-ZEICHNER L, CORNELY O A, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7):828-837. doi:  10.1016/S1473-3099(16)00071-2
[19]

CHOWDHARY A, SINGH P K, KATHURIA S, et al. Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified mucorales species[J]. Antimicrob Agents Chemother, 2015, 59(12):7882-7887. doi:  10.1128/AAC.02107-15
[20]

ESCRIBANO P, MESQUIDA A, LÓPEZ-MONTESINOS S, et al. Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure[J]. Med Mycol, 2023, 61(5):myad045. doi:  10.1093/mmy/myad045
[21]

VEHRESCHILD J J, BIRTEL A, VEHRESCHILD M J G T, et al. Mucormycosis treated with posaconazole: review of 96 case reports[J]. Crit Rev Microbiol, 2013, 39(3):310-324. doi:  10.3109/1040841X.2012.711741
[22]

GONZÁLEZ-RAMOS M M, BERTRÁN-PASARELL J, GUIOT H, et al. Clinical experience with posaconazole in patients with invasive mucormycosis: a case series[J]. P R Health Sci J, 2008, 27(4):328-332.
[23]

SOMAN R, CHAKRABORTY S, JOE G. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series[J]. Int J Infect Dis, 2022, 120:177-178.
[24]

MAERTENS J A, RAAD I I, MARR K A, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi(SECURE): a phase 3, randomised-controlled, non-inferiority trial[J]. Lancet, 2016, 387(10020):760-769. doi:  10.1016/S0140-6736(15)01159-9
[25]

XHAARD A, LANTERNIER F, PORCHER R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study(2003-2008)[J]. Clin Microbiol Infect, 2012, 18(10):E396-E400. doi:  10.1111/j.1469-0691.2012.03908.x
[26]

LEENDERS A C A P, DAENEN S, JANSEN R L H, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections[J]. Br J Haematol, 1998, 103(1):205-212.
[27] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11):1752-1769. doi:  10.3969/j.issn.1001-5256.2015.11.002
[28] 谢倩, 余泽波. 人工肝治疗慢加急性(亚急性)肝衰竭近期疗效及费效比分析[J]. 现代医药卫生, 2020, 36(17):2720-2722,2725. doi:  10.3969/j.issn.1009-5519.2020.17.018
[29]

LEUNIS A, REDEKOP W K, UYL-DE GROOT C A, et al. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study[J]. Eur J Haematol, 2014, 93(3):198-206. doi:  10.1111/ejh.12324
[30]

DONNELLY J P, CHEN S C, KAUFFMAN C A, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium[J]. Clin Infect Dis, 2020, 71(6):1367-1376.
[31]

LIN S J, SCHRANZ J, TEUTSCH S M. Aspergillosis case-fatality rate: systematic review of the literature[J]. Clin Infect Dis, 2001, 32(3):358-366. doi:  10.1086/318483
[32]

JEONG S J, LEE J U, SONG Y G, et al. Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis[J]. Mycoses, 2015, 58(12):746-752. doi:  10.1111/myc.12428
[33]

PEREA J R, DÍAZ DE RADA B S, QUETGLAS E G, et al. Oral versus intravenous therapy in the treatment of systemic mycosis[J]. Clin Microbiol Infect, 2004, 10(Suppl 1):96-106.
[34]

LEWIS R E, CAHYAME-ZUNIGA L, LEVENTAKOS K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study[J]. Mycoses, 2013, 56(6):638-645. doi:  10.1111/myc.12081